Dexlansoprazole
- Atc Codes:A02BC
- CAS Codes:138530-94-6
- PHARMGKB ID:138530-94-6
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Induces
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
North America
Canada: Dexilant; USA: Dexilant.
Drug combinations
Chemistry
Dexlansoprazole: C~16~H~14~F~3~N~3~O~2~S. Mw: 369.36. (+)-2-[(R)-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl] methyl} sulfinyl]-1H-benzimidazole. CAS-138530-94-6.
Pharmacologic Category
Antiulcer Agents and Acid Suppressants; Proton-pump Inhibitors. Substituted Benzimidazole. (ATC-Code: A02BC).
Mechanism of action
Dexlansoprazole is a PPI that suppresses gastric acid secretion by specific inhibition of the (H^+^,K^+^)-ATPase in the gastric parietal cell. By acting specifically on the proton pump, dexlansoprazole blocks the final step of acid production.
Therapeutic use
Healing of all grades of erosive esophagitis (EE). Maintaining healing of EE. Treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD).
Pregnancy and lactiation implications
Use during pregnancy only if clearly needed. Discontinue drug or nursing, taking into consideration importance of drug to mother.
Unlabeled use
Contraindications
Patients with known hypersensitivity to any component of the formulation.
Warnings and precautions
Symptomatic response with dexlansoprazole: does not preclude the presence of gastric malignancy. Long-term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist or spine.